Dr. Reddy’s Laboratories has launched Aripiprazole tablets, USP, in 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, a therapeutic equivalent generic version of Abilify (aripiprazole) tablets in the United States market approved by the US Food & Drug Administration (USFDA). Dr. Reddy’s Aripiprazole tablets 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg are available in bottle count sizes of 30.
The Abilify brand and generic tablets had US sales of approximately $3.1 billion MAT for the most recent twelve months ending in August 2016, according to IMS Health. Abilify is a registered trademark of Otsuka Pharmaceutical Company.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
